Gene therapy for tolerance: high-level expression of donor major histocompatibility complex in the liver overcomes naive and memory alloresponses to skin grafts

EC Cunningham, SS Tay, C Wang, M Rtshiladze… - …, 2013 - journals.lww.com
EC Cunningham, SS Tay, C Wang, M Rtshiladze, ZZ Wang, C McGuffog, J Cubitt…
Transplantation, 2013journals.lww.com
Background The liver has long been recognized as having tolerogenic properties. We
investigated whether recombinant adenoassociated virus (rAAV)–mediated expression of
donor major histocompatibility complex in recipient livers could induce tolerance to donor-
strain grafts. Methods Naive B10. BR (H-2 k) or B10. BR recipients primed with a H-2K b–
expressing (K b+) skin graft were injected with rAAV-expressing H-2K b (rAAV-K b) to induce
K b expression on hepatocytes 7 days before challenge with a K b+ skin graft. K b-specific …
Abstract
Background
The liver has long been recognized as having tolerogenic properties. We investigated whether recombinant adenoassociated virus (rAAV)–mediated expression of donor major histocompatibility complex in recipient livers could induce tolerance to donor-strain grafts.
Methods
Naive B10. BR (H-2 k) or B10. BR recipients primed with a H-2K b–expressing (K b+) skin graft were injected with rAAV-expressing H-2K b (rAAV-K b) to induce K b expression on hepatocytes 7 days before challenge with a K b+ skin graft. K b-specific responses were measured by interferon (IFN)-γ ELISpot and flow cytometric assessment of directly H-2K b reactive cells. Fully allogeneic grafts from C57BL/6 (H-2 b) donors were transplanted onto longstanding B10. BR recipients of K b+ skin to test for linked epitope suppression.
Results
rAAV-K b–treated B10. BR mice accepted K b+ skin grafts with increased median survival time (MST) more than 169 days compared to uninoculated (MST= 18.5 days) and rAAV-K d–treated controls (MST= 19 days). rAAV-K b–treated B10. BR animals primed with K b+ skin grafts also accepted secondary K b+ skin grafts in the long term (MST> 100 days) compared to accelerated rejection in primed, uninoculated mice (MST= 12 days). Treatments did not induce liver pathology, assessed by serum alanine aminotransferase levels and histology. IFN-γ ELISpot analysis of splenocytes from rAAV-K b–treated mice indicated reduced responses to donor K b+ antigen, but protection was not extended to fully allogeneic C57BL/6 skin or heart grafts, even in recipients that had accepted K b+ skin grafts in the long term.
Conclusions
High-level expression of donor major histocompatibility complex in recipient livers promotes tolerance to skin allografts, even in animals primed to produce a memory response. This provides proof of concept for an approach using liver-targeted gene delivery for tolerance induction to donor antigen.
Lippincott Williams & Wilkins